Alternative Data for NovaBay Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 67 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 2 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,171 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,047 | Sign up | Sign up | Sign up |
| X Followers | 4,072 | Sign up | Sign up | Sign up |
| X Mentions | 27 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 129 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 34 | Sign up | Sign up | Sign up |
| Linkedin Employees | 61 | Sign up | Sign up | Sign up |
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally.
| Price | $0.54 |
| Target Price | Sign up |
| Volume | 1,410,000 |
| Market Cap | $68M |
| Year Range | $0.35 - $19.16 |
| Dividend Yield | 0% |
| PE Ratio | 0.1 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
NovaBay Pharmaceuticals Announced 1-for-5 Reverse Stock SplitFebruary 11 - Benzinga |
|
 |
Wondering what's happening in today's after-hours session?February 16 - ChartMill |
 |
NovaBay: 'Hold' Rating As New M&A Direction Could Evolve But With RisksJanuary 12 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 520,000 | 480,000 | 42,000 | -1.3M | -1.3M | -0.230 |
| Q2 '25 | 0 | 38,000 | -38,000 | -1.9M | -1.9M | -0.340 |
| Q1 '25 | 2.3M | 810,000 | 1.5M | 7.7M | -3.3M | -0.400 |
| Q4 '24 | 2.3M | 810,000 | 1.5M | -1.2M | 0 | -0.399 |
| Q3 '24 | 2.4M | 850,000 | 1.6M | -1.2M | -970,000 | -0.590 |
Insider Transactions View All
| Lazar David E. filed to sell 39,925 shares at $0. October 17 '25 |
| Kazley Michael John filed to buy 2,702,703 shares at $0. November 3 '25 |
| R01 Capital LLC filed to buy 2,702,703 shares at $0. November 3 '25 |
| Framework Ventures Management LLC filed to buy 2,702,703 shares at $0. November 3 '25 |
| POPLAR POINT CAPITAL MANAGEMENT LLC filed to buy 1,020,300 shares at $0.5. April 15 '25 |
Similar companies
Read more about NovaBay Pharmaceuticals (NBY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - NovaBay Pharmaceuticals
The Market Cap of NovaBay Pharmaceuticals is $68M.
As of today, NovaBay Pharmaceuticals' PE (Price to Earnings) ratio is 0.1.
Currently, the price of one share of NovaBay Pharmaceuticals stock is $0.54.
The NBY stock price chart above provides a comprehensive visual representation of NovaBay Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovaBay Pharmaceuticals shares. Our platform offers an up-to-date NBY stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, NovaBay Pharmaceuticals (NBY) does not offer dividends to its shareholders. Investors interested in NovaBay Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of NovaBay Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
